Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates

Area of Science:

• Oncology
• Drug Delivery
• Nanomedicine

Background:

• Prostate cancer remains a significant health concern, necessitating innovative therapeutic strategies.
• Targeted drug delivery systems aim to improve treatment efficacy and reduce systemic toxicity.
• HPMA (N-(2-hydroxypropyl) methacrylamide) copolymers offer a versatile platform for drug conjugation.

Purpose of the Study:

• To evaluate the biodistribution, pharmacokinetics, and in vivo efficacy of prostate-cancer-targeted HPMA copolymer/docetaxel (DTX) conjugates.
• To assess the targeting efficiency of PSMA-specific monoclonal antibodies (3F/11) conjugated to HPMA copolymers.
• To determine the therapeutic potential of these targeted conjugates in a prostate cancer xenograft model.

Main Methods:

• Nude mice bearing C4-2 prostate cancer xenografts were used for in vivo studies.
• HPMA copolymer/DTX conjugates were synthesized, with PSMA-specific monoclonal antibodies (3F/11) as the targeting moiety.
• Biodistribution and pharmacokinetic parameters were analyzed over time.
• Tumor growth inhibition was assessed as a measure of efficacy.

Main Results:

• Targeted conjugates demonstrated significantly higher tumor accumulation compared to background organs over time.
• The tumor-to-background organ ratio increased substantially, reaching a 7-fold increase at 48 hours compared to 6 hours.
• All evaluated HPMA copolymer/DTX conjugates showed preliminary tumor growth inhibition in vivo.

Conclusions:

• Prostate-cancer-targeted HPMA copolymer/DTX conjugates exhibit favorable biodistribution and pharmacokinetic properties.
• These targeted conjugates effectively accumulate in tumors, suggesting enhanced drug delivery to the cancer site.
• The conjugates demonstrate promising anti-tumor efficacy, warranting further investigation for prostate cancer treatment.